[Spanish experience with insulin lispro].
Insulin lispro is an analog of human insulin created when the amino acids at positions 28 and 29 of the B-chain of insulin are reversed. The natural sequence in human insulin at these positions is proline at B28 and lysine at B29. At physiologic concentrations, insulin lispro exists in solution as a monomer. As such, it's rate of absorption from subcutaneous sites of injection is greater that of regular insulin. The pharmacokinetic and pharmacodynamic profiles of insulin lispro indicate that it is more rapid-acting, and therefore a more physiological mealtime insulin than regular insulin. In addition, it shows a shorter duration of activity, approximately up to 5 hours. Insulin lispro given 0 to 15 minutes before the meal translate into better glycemic control and less hypoglycemia risk in clinical studies either in type 1 or type 2 diabetes when compare with regular human insulin given 30-45 minutes before meals.
Departamento de Investigación Clínica, Lilly, S.A. Madrid.
J
J
Reviriego Fernández
D000328:Adult; D002986:Clinical Trials as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D061268:Insulin Lispro; D007336:Insulin, Isophane / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D013997:Time Factors
D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D007336:Insulin, Isophane